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Opioid mechanismThis study aimed to assess the possible systemic antinociceptive activity of mangiferin and to clarify the un-
derlying mechanism, using the acute models of chemical (acetic acid, formalin, and capsaicin) and thermal
(hot-plate and tail-ﬂick) nociception in mice. Mangiferin at oral doses of 10 to 100 mg/kg evidenced signif-
icant antinociception against chemogenic pain in the test models of acetic acid-induced visceral pain and in
formalin- and capsaicin-induced neuro-inﬂammatory pain, in a naloxone-sensitive manner, suggesting the
participation of endogenous opiates in its mechanism. In capsaicin test, the antinociceptive effect of
mangiferin (30 mg/kg) was not modiﬁed by respective competitive and non-competitive transient receptor
potential vanilloid 1 (TRPV1) antagonists, capsazepine and ruthenium red, or by pretreatment with L-NAME,
a non-selective nitric oxide synthase inhibitor, or by ODQ, an inhibitor of soluble guanylyl cyclase. However,
mangiferin effect was signiﬁcantly reversed by glibenclamide, a blocker of KATP channels and in animals
pretreated with 8-phenyltheophylline, an adenosine receptor antagonist. Mangiferin failed to modify the
thermal nociception in hot-plate and tail-ﬂick test models, suggesting that its analgesic effect is only periph-
eral but not central. The orally administered mangiferin (10–100 mg/kg) was well tolerated and did not im-
pair the ambulation or the motor coordination of mice in respective open-ﬁeld and rota-rod tests, indicating
that the observed antinociception was unrelated to sedation or motor abnormality. The ﬁndings of this study
suggest that mangiferin has a peripheral antinociceptive action through mechanisms that involve endoge-
nous opioids, KATP-channels and adenosine receptors.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Mangifera indica L. (mango, Anacardiaceae) is an important me-
dicinal and fruiting tree that grows abundantly in the tropical and
subtropical regions. The medicinal usage of its leaf and stem bark ex-
tracts have been reported in several traditional systems of medicine
(Scartezzini and Speroni, 2000; Ojewole, 2005). The main polyphenol
present in extracts is mangiferin with C-glucosyl linkage and polyhy-
droxy component that determine its strong antioxidant and anti-
inﬂammatory properties (Garrido et al., 2001). Mangiferin is also
present in some other medicinal herbs, inﬂuencing their therapeutic
and preventive properties. A number of biological activities ofand Pharmacology, Faculty of
e Melo 1127, Rodolfo Teóﬁlo,
341; fax: +55 85 3366 8333.
rights reserved.mangiferin have been suggested, including antioxidant, antiviral,
antitumor, anti-allergic, antidiabetic, hepato- and cardioprotective,
anti-inﬂammatory and immunomodulatory effects (Sato et al.,
1992; Guha et al., 1996; Garcia et al., 2003; Pardo-Andreu et al.,
2006; Das et al., 2012; Vyas et al., 2012). Furthermore, mangiferin
(10–40 mg/kg) has been shown to signiﬁcantly improve the
scopolamine-associated loss of learning ability in Elevated plus
Maze, Water Maze, and Passive Shock Avoidance behavioral models
through inhibitions of whole brain acetyl cholinesterase and lipid
peroxidation, and by restoration of reduced glutathione (Jung et al.,
2009; Biradar et al., 2012). We previously showed that mangiferin
affords gastroprotection against ethanol or indomethacin-induced
gastric damage (Carvalho et al., 2007), exerts prokinetic action on
gastrointestinal transit (Cavalcante Morais et al., 2012), and
neuroprotection in ketamine-induced schizophrenia model (Rao et
al., 2012). Earlier works suggest that pain is one of the most impor-
tant symptoms of inﬂammatory disease (Vane and Botting, 1990;
20 S.C. Lopes et al. / Pharmacology, Biochemistry and Behavior 110 (2013) 19–26Weisburger, 2002), and oxidative stress modiﬁes experimental
nociception (Viggiano et al., 2005; Hacimuftuoglu et al., 2006;
Garrido-Suárez et al., 2010; Ma et al., 2009). In this regard, a recent
study has shown that mangiferin can modulate or inhibit several
key oxidant and inﬂammatory pathways such as Nrf2–NFκB signaling
(Das et al., 2012), suggesting its ability to suppress pain. Acute noci-
ceptive, inﬂammatory, and neuropathic pain all depend to some
degree on the peripheral activation of primary sensory afferent
neurons, which express a variety of inhibitory neuroreceptors such
as opioid, alpha-adrenergic, cholinergic, adenosine and cannabinoid
receptors, and agonists for these receptors also represent viable
targets for drug development (Sawynok, 2003). Potential utility of
mangiferin for treating and preventing neuropathic pain has been
proposed based on preclinical studies that show the preventive ef-
fects of mangiferin on tumor necrosis factor α-induced IκB degrada-
tion and the binding of nuclear factor κB to DNA, which induces the
transcription of genes implicated in the expression of some mediators
and enzymes involved in inﬂammation, pain, oxidative stress and
synaptic plasticity (Garrido-Suárez et al., 2010).
Current therapy for inﬂammatory pain includes the peripheral appli-
cation of opioid receptor agonists. Activation of opioid receptors modu-
lates voltage-gated ion channels, and can also inﬂuence ligand-gated ion
channels like the transient receptor potential vanilloid type 1 (TRPV1)
(Endres-Becker et al., 2007). Dar et al. (2005) reported for ﬁrst time,
the antinociceptive effect of mangiferin and its derivatives in mice,
using the acetic acid-inducing writhing and hot-plate tests. Only
mangiferin but not the derivatives manifested signiﬁcant naloxone-
sensitive antinociception after a subcutaneous dose of 42.2 mg/kg
mangiferin, indicating an endogenous opioid-related mechanism. How-
ever, the antinociceptive efﬁcacy of mangiferin on formalin- and
capsaicin-induced neuropathic and inﬂammatory pain is unknown,
wherein primary sensory afferent neurons can be activated by a range
of inﬂammatory mediators such as prostanoids, bradykinin, ATP, hista-
mine, and serotonin, and inhibiting their actions represents a strategy
for the development of analgesics (Priestley and Hunter, 2006; Ortega-
Álvaro et al., 2012).
To have greater insights into the mechanism (s) and the sites of
action, this study examined the pain modulator effect of mangiferin,
using several mouse models of chemical and thermal nociception.
2. Materials and methods
2.1. Plant material and isolation of mangiferin
Mangiferin (Fig. 1) used in this study was extracted and isolated
from the bark ofM. indica L. (Anacardiaceae) as per procedures reported
earlier (Barreto et al., 2008). A voucher specimen (# 32628) of the plant
material authenticated by Dr. Francisco Edson de Paula has been depos-
ited at the Herbário Prisco Bezerra of the Federal University of Ceara.
The isolated MGF was approximately of 95% purity having the molecu-
lar weight (MW) 422.5 and melting point (m.p.) 271 °C.
2.2. Animals
Male Swiss mice (20–25 g) obtained from the Central Animal
House of Federal University of Ceará, Brazil were used. Experimental
groups consisted of 8 animals per group. They were housed inFig. 1. Chemical structure of mangiferin.environmentally controlled conditions (24 ± 2 °C, 12 h light/12 h
dark cycle), with free access to standard diet (Purina Chow) and tap
water. Each animal was used only once for experimentation. Mice
were deprived of food for 15 h before the experimentation. The ex-
perimental protocols were approved by the Animal Care and Use
Committee of the Federal University of Ceará in accordance with the
ethical guidelines of the International Association for the Study of
Pain (Proc. No. 24/2012). All efforts were made to minimize animal
suffering and reduce the number of animals used.
2.3. Drugs and chemicals
Acetic acid, formaldehyde, capsaicin, capsazepine, ruthenium red,
L-arginine, NG-nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]
oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), diazoxide, glibenclamide,
and 8-phenyltheophylline were purchased from Sigma-Aldrich Inc.
(St. Louis, MO, USA). The other drugs were from Morphine hydrochlo-
ride (Dimorf®, Cristalia, SP, Brazil), naloxone chloridrate (Narcan®,
Cristalia, SP, Brazil), diazepam (Valium®, Roche, SP, Brazil). All other
chemicals used were of analytical grade. Capsaicin was dissolved in a
vehicle comprising of ethanol, Tween 80 and normal saline (1:1:8).
Mangiferin was dissolved in 2% Tween 80 in saline. All other drugs
were dissolved in normal saline. The vehicles used alone had no effects
per se on the nociceptive responses in mice.
2.4. Nociceptive tests
The analgesic activity of mangiferin was evaluated on the chemi-
cal nociception in the animal models of acetic acid-induced writhing,
capsaicin and formalin-induced hind paw licking, and on the thermal
nociception using the tail-ﬂick and hot-plate tests. Conscious (un-
anesthetized) mice were used in all the nocifensive tests. The doses
selection for mangiferin and positive controls were based on litera-
ture ﬁndings. Control groups were treated with a similar volume of
the vehicle that had been used to dilute this compound.
2.4.1. Acetic acid-induced writhing
The acetic acid-induced nociception was performed as described
previously by Koster et al. (1959). Groups of mice (n = 8)were treated
with vehicle (2% Tween 80, 10 mL/kg, p.o.) or mangiferin (10, 30 and
100 mg/kg, p.o.) 60 min before or morphine (5 mg/kg, s.c.) 30 min be-
fore the administration of acetic acid (0.6%, 10 mL/kg, i.p.). The number
of abdominal constrictions (writhing) was counted for each animal,
starting 10 min after acetic acid injection over a period of 20 min.
In order to evaluate the participation of the opioid system in the
antinociceptive property of mangiferin, different groups of mice were
pretreatedwith naloxone (2 mg/kg, i.p.) 15 min before the administra-
tion of mangiferin (30 mg/kg, p.o.) or morphine (5 mg/kg, s.c.).
2.4.2. Formalin-induced paw licking
The formalin-induced nociception was performed as described pre-
viously by Hunskaar and Hole (1987). Groups of mice (n = 8) were
treated with vehicle (10 mL/kg, p.o.) or mangiferin (10, 30 and
100 mg/kg, p.o.) 60 min before or morphine (5 mg/kg, s.c.) 30 min be-
fore the administration of 20 μl of 1% formalin (in 0.9% saline) into the
plantar surface of the right hind paw. The duration of paw licking (s)
as an index of painful response was determined at 0–5 min (early
phase, neurogenic) and 20–25 min (late phase, inﬂammatory) after for-
malin injection. In order to verify the possiblemechanismofmangiferin
antinociception (30 mg/kg) animal groupswere pretreatedwith nalox-
one (2 mg/kg, s.c.), 15 min before the mangiferin or morphine.
2.4.3. Capsaicin test
The capsaicin-induced nociceptionwas performed as described pre-
viously by Santos and Calixto (1997). Groups of mice (n = 8) were
treated with vehicle (2% Tween 80, 10 ml/kg, p.o.) or mangiferin (10,
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30 min before the intraplantar administration of capsaicin (1.6 μg
in 20 μl). The time the animals spent licking the injected paw in
seconds (s) was registered for a period of 5 min.
To elucidate the possible mechanism in the antinociceptive effect
of mangiferin in capsaicin test, the effects of morphine (5 mg/kg,
s.c.), diazoxide (2 mg/kg, i.p.), L-arginine (600 mg/kg, i.p.), or the
appropriate antagonist, naloxone (2 mg/kg, i.p., a non-selective
μ-opioid receptor antagonist), capsazepine (5 mg/kg, i.p., a competi-
tive TRPV1 channel antagonist), ruthenium red (3 mg/kg, s.c., a
non-competitive TRPV1 antagonist), 8-phenyltheophylline (8 mg/kg,
i.p., the adenosinergic antagonist), glibenclamide (2 mg/kg, i.p., a
blocker of KATP-channels), L-NAME (20 mg/kg, i.p., a non-selective
NOS inhibitor) and ODQ (1 mg/kg, i.p., a blocker of soluble cGMP) or
their combinations were analyzed. Sixty minutes after mangiferin
(30 mg/kg) or 30 min following the agonist/antagonist drug adminis-
trations, capsaicin test was carried out as described earlier. When
drugs were combined with mangiferin, the respective agent was ad-
ministered 15 min before mangiferin. Vehicle-treated controls that
received capsaicin were also included. The dose selections for capsai-
cin (1.6 μg), the agonist and antagonist drugs were based on our
pilot experimentation and from literature citations.2.4.4. Hot-plate and tail-ﬂick tests
The hot-plate test (Eddy and Leimbach, 1953) and tail-ﬂick test
(Janssen et al., 1963) were used with slight modiﬁcations to evaluated
de antinociceptive effect of mangiferin. The time taken to lick either
hind paw or to jump up (reaction time) when placed on a hot-plate
(Ugo Basile, model-DS 37, Italy) maintained at 51 ± 0.5 °C was
recorded. In the tailﬂick test, the time taken toﬂick the tail (the reaction
time)when the tail was immersed (3–4 cm from its tip) in awater bath
at 55 °C was noted. Mice showing a pretreatment reaction time greater
than 15 s in the hot plate test and 5 s in the tail ﬂick test were not used
in the experiment. A cut off time of 45 s and 10 swere used to avoid tis-
sue damage in the hot plate test and tail ﬂick tests, respectively. Animal
groups (n = 8) were treated with the vehicle (10 ml/kg, p.o.),
mangiferin (10, 30 and 100 mg/kg, p.o.) or morphine (5 mg/kg, s.c.)
and the reaction time was measured before and after 30, 60, 90, and
120 min of drug administrations.40
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The open-ﬁeld test (Capaz et al., 1981) was used to evaluate the
effect of mangiferin on locomotor activity of mice. The apparatus
consisted of an acrylic box (transparent walls and black ﬂoor) mea-
suring 30 × 30 × 15 cm2 and divided in nine squares of equal area.
The number of squares crossed with all paws was counted in a
4 min session. Animal groups (n = 8) were treated with the vehicle
(10 ml/kg, p.o.) or mangiferin (10, 30 and 100 mg/kg, p.o.) 60 min
before or diazepam (1 mg/kg, i.p.) 30 min before the test.0
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Fig. 2. Effects of mangiferin and morphine on acetic acid-induced writhing test in mice.
The animals were pretreated with mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) or ve-
hicle 60 min or with morphine (Morph, 5 mg/kg, s.c.) 30 min before the acetic acid
(0.6%, 10 ml/kg, i.p.). Naloxone (Nalox, 2 mg/kg, i.p.) was administered 15 min before
morphine or mangiferin (30 mg/kg). The number of abdominal constrictions (writh-
ings) was counted over a period of 20 min. All data are mean ± S.E.M. (n = 8).
*p b 0.05 compared with vehicle group. #p b 0.05 compared with morphine or
mangiferin at dose of 30 mg/kg. ANOVA followed by Newman Keul's test.2.6. Rota-rod test
The rota-rod test was carried out according to the method
described earlier (Rosland et al., 1990). The apparatus consisted of a
horizontal bar with a diameter of 5 cm, subdivided into four compart-
ments (Ugo Basile, model 7650, Italy). The mice were placed on the
bar rotating at a speed of 4 rpm and mice that were able to remain
on the rod longer than 120 s were selected 24 h before the test. Ani-
mal groups (n = 8) were treated with the vehicle (10 ml/kg, p.o.) or
mangiferin (10, 30 and 100 mg/kg, p.o.) 60 min before or diazepam
(1 mg/kg, i.p.) 30 min before the test. Each animal was tested on
the rota-rod for the number of falls, during a 2 min period.2.7. Statistical analysis
The results are presented as the mean ± S.E.M. for 8 animals per
group. Statistical comparisons of the data were performed by one-way
analysis of variance (ANOVA), followed by Newman Keul's test for mul-
tiple comparisons. Differences were considered statistically signiﬁcant
at p b 0.05.
3. Results
3.1. Writhing test
In acetic acid-induced writhing test, mangiferin suppressed the
mean number of writhes, when compared to vehicle-treated control
group (Fig. 2). These were in the order of 49.13 ± 6.99, 32.13 ± 7.46,
16.78 ± 6.36, and 7.87 ± 3.63, respectively, for the controls and
mangiferin at the tested doses of 10, 30 and 100 mg/kg. The positive
control group treated with morphine (5 mg/kg, s.c.) also manifested
signiﬁcantly diminished number of writhes (1.12 ± 0.44). Naloxone
(2 mg/kg, i.p.) signiﬁcantly inhibited the antinociceptive effect of mor-
phine and mangiferin (30 mg/kg).
3.2. Formalin test
In formalin test, vehicle treated animals showed the mean licking
times (s) of 80.14 ± 9.19 in the ﬁrst phase and 44.00 ± 8.31 in the sec-
ond phase (Fig. 3). Pretreatment with mangiferin 30 and 100 mg/kg
caused signiﬁcant diminutions of both ﬁrst phase (neurogenic)
(31.50 ± 6.16 s and 53.40 ± 5.49 s, respectively) and second phase
(inﬂammatory) (2.83 ± 1.76 s and 7.17 ± 3.86 s, respectively) pain
responses (Fig. 3).Morphine (5 mg/kg), the reference standard also sig-
niﬁcantly suppressed the formalin-response at both phases (ﬁrst phase,
12.67 ± 2.11 s and second phase, 5.86 ± 2.73 s). Naloxone (2 mg/kg,
i.p.) signiﬁcantly blocked the antinociceptive effect of morphine and
mangiferin (30 mg/kg) at both phases of the formalin test (Fig. 3).
3.3. Capsaicin test
Fig. 4 shows the suppressive effect of mangiferin on paw-licking
response to subplantar injection of capsaicin (1.6 μg). The vehicle
treated mice showed the paw-licking response of 96.00 ± 11.06 s.
Mangiferin signiﬁcantly reduced the paw-licking response at doses
1st Phase 2nd Phase
0
20
40
60
80
100
Vehicle
MGF 10 mg/kg
MGF 30 mg/kg
MGF 100 mg/kg
Nalox 2 mg/kg + Morph 5 mg/kg
Nalox 2 mg/kg + MGF 30 mg/kg
*
*
*
# #
*
*
*
# #
Morph 5 mg/kg
Pa
w
 li
ck
in
g 
tim
e 
(s)
Fig. 3. Effects of mangiferin and morphine on formalin test in mice. The animals were
pretreated with mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) or vehicle 60 min or with
morphine (Morph, 5 mg/kg, s.c.) 30 min before the administration of 1% formalin (20 μl
in 0.9% saline) into the plantar surface of the right hind paw. Naloxone (Nalox, 2 mg/kg,
i.p.) was administered 15 min before morphine or mangiferin (30 mg/kg). The duration
of paw licking (s) was determined at 0–5 min (ﬁrst phase) and 20–25 min (second
phase) after formalin injection. All data are mean ± S.E.M. (n = 8). *p b 0.05 compared
with vehicle group. #p b 0.05 compared with morphine or mangiferin at dose of
30 mg/kg. ANOVA followed by Newman Keul's test.
20
40
60
80
100
Vehicle
MGF 30 mg/kg
*
*
C
#
#
Diazoxide 2 mg/kg
GLIB 2 mg/kg + Diazoxide 2 mg/kg
GLIB 2 mg/kg + MGF 30 mg/kg
8-PH 8 mg/kg
*
#8-PH 8 mg/kg + MGF 30 mg/kg
Pa
w
 li
ck
in
g 
tim
e 
(s)
0
20
40
60
80
100
Vehicle
MGF30 mg/kg
CPZ 5 mg/kg
RR 3 mg/kg
RR 3 mg/kg + MGF 30 mg/kg
*
*
*
*
A
*
CPZ 5 mg/kg + MGF30 mg/kg
Pa
w
 li
ck
in
g 
tim
e 
(s)
0
20
40
60
80
100
*
Vehicle
MGF 30 mg/kg
L-ARG 600 mg/kg
L-NAME 20 mg/kg + MGF 30 mg/kg
L-NAME 20 mg/kg + L-ARG 600 mg/kg
*
B
ODQ 1 mg/kg
#
*
*
Pa
w
 li
ck
in
g 
tim
e 
(s)
ODQ 1 mg/kg + MGF 30 mg/kg
22 S.C. Lopes et al. / Pharmacology, Biochemistry and Behavior 110 (2013) 19–2610 mg/kg (27.29 ± 7.00 s), 30 mg/kg (32.60 ± 3.69 s) and 100 mg/kg
(28.40 ± 7.78 s) when compared to vehicle-treated control. Morphine
(5 mg/kg) greatly reduced the paw-licking response (3.25 ± 2.41 s)
and appeared much more potent than to mangiferin. Naloxone
(2 mg/kg, i.p.) signiﬁcantly inhibited the antinociceptive effects of both
morphine and mangiferin (30 mg/kg) (Fig. 4) The capsaicin-induced
nociception was also signiﬁcantly blocked by capsazepine and rutheni-
um red, the respective competitive and non-competitive TRPV1 antago-
nists (Fig. 5A). However, their combinations with mangiferin failed to
modify mangiferin antinociception. Similar to mangiferin (30 mg/kg),
L-arginine (600 mg/kg) alone caused signiﬁcant inhibition of capsaicin-
induced nociception (Fig. 5B). However, in mice pretreated with
L-NAME, a non-selective NOS inhibitor, the antinociceptive effect of
L-arginine but not ofmangiferinwas signiﬁcantly reversed. Further, a sol-
uble cGMP inhibitor ODQ (1 mg/kg) failed to block the antinociceptive
effect of mangiferin. Like mangiferin, diazoxide (2 mg/kg), an opener
of KATP-channels signiﬁcantly inhibited the nociception induced by
capsaicin, which was however, reversed in animals pretreated with
glibenclamide (2 mg/kg), a blocker of KATP channels (Fig. 5C).Mangiferin
antinociception was signiﬁcantly blocked by glibenclamide as well as by
8-phenyltheophylline (8 mg/kg), an adenosine receptor antagonist.0
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Fig. 4. Effects of mangiferin and morphine on capsaicin test in mice. The animals were
pretreated with mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) or vehicle 60 min or with
morphine (Morph, 5 mg/kg, s.c.) 30 min before the administration of capsaicin (1.6 μg,
20 μl) into the right hind paw. Naloxone (Nalox, 2 mg/kg, i.p.) was administered
15 min before morphine or mangiferin (30 mg/kg). The time the animals spent licking
the injected paw was registered for a period of 5 min. All data are mean ± S.E.M.
(n = 8). *p b 0.05 compared with vehicle group. #p b 0.05 compared with morphine
or mangiferin at dose of 30 mg/kg (ANOVA and Newman Keul's test).
0
Fig. 5.Mechanistic studies on mangiferin antinociception in capsaicin test with mice:
A. Effects of pretreatment with TRPV1 selective antagonist capsazepine or non-
selective antagonist ruthenium red (RR) and their combinations with mangiferin;
B. Pretreatment effects of NOS inhibitor L-NAME or soluble cGMP inhibitor ODQ and
their combinations with mangiferin; C. Pretreatment effects of KATP channel blocker
glibenclamide or adenosinergic antagonist 8-Phenyltheophylline (8-PH) and their
combinations with mangiferin. The animals were pretreated with vehicle or
mangiferin (MGF 30 mg/kg, p.o.) 60 min before or with glibenclamide (GLB, 5 mg/kg, i.p.),
capsazepine (CPZ, 5 mg/kg, i.p.), ruthenium red (RR, 3 mg/kg, s.c.), L-arginine (L-ARG,
600 mg/kg, i.p.), L-NAME (20 mg/kg, i.p.), ODQ (1 mg/kg, i.p.), diazoxide (2 mg/kg, i.p.),
and 8-phenyltheophylline (8-PH, 8 mg/kg, i.p.), 30 min before the administration of capsai-
cin (1.6 μg, 20 μl) into the right hindpaw.When drugs were combined, the respective agent
was administered 15 min before mangiferin. The time in seconds (s) the animals spent lick-
ing the injectedpawwas registered for a periodof 5 min. All data aremean ±S.E.M. (n = 8).
*p b 0.05 compared with vehicle group. #p b 0.05 compared with morphine or mangiferin
at the dose of 30 mg/kg (ANOVA and Newman Keul's test).3.4. Hot-plate and tail-ﬂick tests
In the hot-plate and tail-ﬂick test models of thermal nociception,
whilemangiferin (10, 30 and 100 mg/kg, p.o.) pretreatmentmanifested
Table 1
Effects of mangiferin and morphine on hot-plate test in mice.
Groups Reaction time (s) after the drug administration
0 min 30 min 60 min 90 min 120 min
Vehicle 17.31 ± 1.53 18.61 ± 2.88 18.60 ± 1.85 18.15 ± 1.20 20.63 ± 1.98
MGF 10 mg/kg 17.29 ± 1.66 18.01 ± 1.98 23.35 ± 2.45 23.84 ± 2.71 25.21 ± 2.44
MGF 30 mg/kg 16.05 ± 1.59 20.34 ± 2.44 21.75 ± 1.53 23.51 ± 2.96 27.48 ± 4.06
MGF 100 mg/kg 15.59 ± 1.48 22.89 ± 2.45 23.43 ± 2.37 25.26 ± 1.31 18.43 ± 1.67
Morphine 5 mg/kg 17.41 ± 6.35 44.99 ± 0.01⁎ 38.76 ± 2.76⁎ 35.08 ± 3.83⁎ 26.14 ± 3.23
Mice were pretreated with vehicle, mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) 60 min or morphine (5 mg/kg, s.c.) 30 min before the test. Data are expressed as mean ± S.E.M. of
reaction time in seconds (s) of 8 animals.
⁎ p b 0.05 different from vehicle group (ANOVA followed by Newman Keul's test).
Table 2
Effects of mangiferin and morphine on tail-ﬂick test in mice.
Groups Reaction time (s) after the drug administration
0 min 30 min 60 min 90 min 120 min
Vehicle 2.76 ± 0.32 2.79 ± 0.38 2.56 ± 0.49 2.34 ± 0.21 2.36 ± 0.33
MGF 10 mg/kg 2.97 ± 0.30 2.90 ± 0.13 2.89 ± 0.27 3.22 ± 0.30 2.75 ± 0.11
MGF 30 mg/kg 2.77 ± 0.36 2.20 ± 0.14 2.92 ± 0.27 3.24 ± 0.18 3.59 ± 0.27
MGF 100 mg/kg 2.50 ± 0.33 3.27 ± 0.50 3.47 ± 0.09 3.70 ± 0.10 3.58 ± 0.08
Morphine 5 mg/kg 3.15 ± 0.47 5.23 ± 0.49⁎ 6.49 ± 0.94⁎ 7.13 ± 0.74⁎ 5.63 ± 0.75⁎
Mice were pretreated with vehicle, mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) 60 min or morphine (5 mg/kg, s.c.) 30 min before the test. Data are expressed as mean ± S.E.M. of
reaction time in seconds (s) of 8 animals.
⁎ p b 0.05 different from vehicle group (one way ANOVA followed by Newman Keul's test).
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opioid agonist, morphine (5 mg/kg, s.c.) demonstrated signiﬁcant
antinociception at the time points of 30, 60, 90 and 120 min (Tables 1
and 2).
3.5. Open-ﬁeld and rota-rod tests
Mangiferin administered at the oral dose of 10, 30 and 100 mg/kg
failed to produce any signiﬁcant effect on locomotion frequency or on
motor coordination on rota-rod in mice, indicating that the observed
antinociception was unrelated to sedation or motor abnormality
(Table 3). In contrast, diazepam (1 mg/kg, i.p.) signiﬁcantly lowered
the locomotion frequency (evidenced by reduced number of crossings)
and motor coordination (evidenced by increased number of falls).
4. Discussion
Mangiferin was evaluated for analgesic activity in mice using
experimental models of chemogenic and thermal nociception. The
data from this investigation conﬁrmed the antinociceptive effect of
mangiferin against chemically induced nociception but not the ther-
mal pain, in a naloxone reversible manner suggesting a peripheral
opioid mechanism. Tail ﬂick-induced thermal nociception has beenTable 3
Effects of mangiferin and diazepam on open-ﬁeld test and rota-rod test in mice.
Groups Open-ﬁeld test Rota-rod test
Number of crossing Number of falls
Vehicle 45.25 ± 5.40 0.37 ± 0.26
MGF 10 mg/kg 44.25 ± 4.81 0.50 ± 0.27
MGF 30 mg/kg 38.38 ± 3.62 0.50 ± 0.27
MGF 100 mg/kg 43.25 ± 4.57 0.37 ± 0.26
Diazepam 1 mg/kg 23.17 ± 5.36⁎ 2.67 ± 0.33⁎
Micewere pretreatedwith vehicle,mangiferin (MGF, 10, 30 or 100 mg/kg, p.o.) 60 min or
diazepam (1 mg/kg, i.p.) 30 min before the test. Data are expressed as mean ± S.E.M. of
number of crossing (open-ﬁeld test) or number of falls (rota-rod test) of 8 animals.
⁎ p b 0.05 different from vehicle group (one way ANOVA followed by Newman
Keul's test).considered to involve spinal mechanisms while Eddy's hot-plate-
induced thermal nociception involves the supraspinal mechanisms
(Yaksh and Rudy, 1976). In both these experimental models,
mangiferin failed to demonstrate antinociceptive activity at any one
of the test doses, indicating that it had no spinal or supraspinal level
of action. However, this observation differs from the studies of Dar et
al. (2005) that reported a naloxone reversible antinociception against
thermal pain in hot-plate test, following a single dose (42.2 mg/kg)
subcutaneous/intraperitoneal injection. This discrepancy may be due
to differences in experimental conditions and the route of mangiferin
delivery. It is likely that enteral or parenteral administration may in-
ﬂuence the plasma concentration kinetics differently and thus the
test drug bioactivity. However, there is no available literature data
on the absorption kinetics of mangiferin. Since the antinociceptive ac-
tivity of mangiferin occurs without activation of opioid receptors in
the central nervous system (CNS), centrally mediated side effects
may be absent with peripheral opioid activity. Acting as a peripheral
opioid agonist, mangiferin may possibly activate peripheral opioid re-
ceptors on sensory nerve ﬁbers and suppress capsaicin algesia by de-
creasing the excitability of sensory nerves and/or inhibiting release
of pro-inﬂammatory neuropeptides. Thus an important ﬁnding from
our study is the demonstration of peripheral opioidergic system in-
volvement in the antinociceptive effect of mangiferin, which is possi-
bly manifested through its anti-inﬂammatory and antioxidant effects
in experimental models of chemogenic pain.
From this study, it could be assumed that the antinociceptive action
of mangiferinwas purelymediated through blockade of peripheral pain
pathways without the any involvement of central action. In this regard,
a recent pharmacokinetic study (Zajac et al., 2013) using the qualitative
methods of thin-layered-chromatography and UV/VIS spectrophotom-
etry failed to tracemangiferin in the brain fractions, whichmakes it un-
likely that the compound traverse the blood–brain barrier after being
systemically administered (300 mg/kg, i.p.) and concluded that it is im-
probable that mangiferin could act via direct interaction with central
neural components, but rather has peripheral, target speciﬁc functions
which could be secondarily reﬂected in brain metabolism. Because of
this, the reported neuropharmacological effects ofmangiferin following
systemic administration and the claims or suggestions made on its
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and for the improvement of cognitive function (Biradar et al., 2012;
Rao et al., 2012; Jung et al., 2009) need further analysis and explanation.
Pain is one of the most important symptoms of inﬂammatory dis-
ease because it directly affects people's daily lives and is the primary
reason why patients seek medical expertise (Vane and Botting, 1990;
Weisburger, 2002). Studies also suggest that oxidative stress modiﬁes
experimental nociception (Viggiano et al., 2005; Garrido-Suárez et al.,
2010; Ma et al., 2009) and antioxidants ameliorate nociception
(Rokyta et al., 2003; Hacimuftuoglu et al., 2006). Known antioxidants
like PBN (phenyl-N-tert-butylnitrone), TEMPOL (4-hydroxy-2,2,6,6-
tetramethylpiperidine-1-oxy) and NAC (N-acetyl-L-cysteine) not only
are effective in suppressing neuropathic and inﬂammatory pain
(Viggiano et al., 2005; Hacimuftuoglu et al., 2006) but may even permit
a decrease in the doses of analgesics and prevent the negative impact
of reactive oxygen species on nociception (Rokyta et al., 2003).
Mangiferin's xanthonoid structure with C-glucosyl linkage and polyhy-
droxy component is believed to be crucial for its free radical-scavenging
ability leading to a potent antioxidant effect. The antinociceptive poten-
tial of mangiferin observed in present investigation is consistent with
earlier reports on plant-derived substances like citronellal, a monoter-
pene (Brito et al., 2012), quercetin, a bioﬂavonoid (Valério et al.,
2009), and the polyphenolic resveratrol (Granados-Soto et al., 2002)
that largely possess the antioxidant property. Therefore, studying the
pain modulation effects of antioxidants is considered an emerging
area of interest.
In the present experiments, nociceptive responding, indicated by
licking the affected hindlimb, was quantiﬁed for 30 min after forma-
lin injection or for 5 min following intraplantar capsaicin or the num-
ber of abdominal constrictions (writhes) for 20 min, following
intraperitoneal acetic acid. Mangiferin was effective in attenuating
acute neurogenic phase, and tonic inﬂammatory phase of the forma-
lin response and similarly the neuropathic and inﬂammatory pain in-
duced by capsaicin as well the writhing response induced by acetic
acid. The capsaicin test is a particularly relevant model since it is a se-
lective TRPV1 agonist capable of inducing an acute nociception and
neurogenic inﬂammation in experimental animals and pain in
humans through activation of capsaicin-sensitive peripheral afferent
ﬁbers or sensory neurons (Saadé et al., 2002) that play an important
role in nociceptive pain processing, thus involving the peripheral ner-
vous system (Gold and Gebhart, 2010). Mangiferin, given orally, elic-
ited a dose-unrelated antinociceptive effect on the capsaicin-induced
neurogenic paw-licking response, just as observed in the second
phase (inﬂammatory) of formalin test. Mangiferin was also effective
in inhibiting the nociception induced by intraperitoneal acetic acid,
conﬁrming previously reported results (Dar et al., 2005). The writh-
ing test is frequently used to evaluate visceral pain because acetic
acid directly activates visceral and somatic nociceptors innervating
the peritoneum and induces the inﬂammation in visceral organs,
which is mediated by inﬂammatory mediators such as prostaglan-
dins, bradykinin, substance P and cytokines (Le Bars et al., 2001).
Reports suggest that pro-oxidant species may be important mediators
of tissue injury-induced algesia in rodents, and antioxidants are
effective analgesics in neuropathic and inﬂammatory pain models
(Hacimuftuoglu et al., 2006). Besides acting as an antioxidant,
mangiferin is known to inhibit several key inﬂammatory pathways
such as Nrf2–NFκB signaling (Das et al., 2012). Thus the antioxidant
and anti-inﬂammatory properties also may, in part, account for the
antinociceptive activity of mangiferin.
It is currently accepted that an endogenous opioid analgesic system
is present at peripheral level (Smith, 2008; Alves et al., 2012), andmost
of opioid antinociceptive effects are mediated via activation of opioid
receptors (Stein and Lang, 2009) and opioid receptors have been iden-
tiﬁed on peripheral terminals of afferent nerves, which can be the sites
of the intrinsic modulation of nociception (Vadivelu et al., 2011). At-
tempts to mimic or augment such peripheral analgesia may potentiallylead to analgesic effects in the absence of the central adverse effects
caused by opioids. In capsaicin test, the antinociceptive effect of
mangiferin was not modiﬁed by respective selective and non-selective
TRPV1 antagonists capsazepine or ruthenium red, but was reversed by
naloxone, a non-selective μ-opioid receptor antagonist, suggesting an
opioid mechanism. Mangiferin may indirectly inhibit/attenuate the
TRPV1 receptor in the skin sensory afferents to induce antinociception
through stimulation of endogenous peripheral opioid system and in-
volving the pathways that include adenosinergic, nitric oxide, and the
opening of ATP-sensitive potassium channels. Therefore, so as to have
greater insights into the molecular mechanism by which mangiferin
promotes peripheral antinociception, the present study examined ﬁrst
the possible participation of NO/cGMP/K + ATP pathway that appears
to involve the peripheral antinociception produced by opioids
(Ferreira et al., 2005; Rodrigues and Duarte, 2000). In capsaicin test,
our results show that pretreatments with a KATP blocker, glibenclamide
but not the nonspeciﬁc NOS inhibitor, L-NAME, or the soluble guanylyl
cyclase inhibitor, ODQ could effectively reverse the antinociceptive ef-
fect of mangiferin, suggesting that mangiferin's antinociception results
from the modulation of KATP currents.
The activation of adenosine receptors in peripheral afferents is also
important in modulating pain and studies report on the release of en-
dogenous adenosine in the presence of morphine (Sawynok, 1998;
Peart and Gross, 2005). Adenosine has recently been proposed to be a
signiﬁcant anti-inﬂammatory autacoids released peripherally under
conditions of inﬂammation (Cronstein, 1994). The antinociceptive ac-
tions of adenosine and adenosine analogs in animal models have been
reported that could be reversed by caffeine or 8-phenyltheophylline
(Homayounfar et al., 2005). This mechanism also seems to participate
inmangiferin's antinociception, because pre-treatmentwith the adeno-
sine antagonist, 8-phenyltheophylline effectively reversed its effect.
Postoperative pain management is an essential part of surgical
management because inadequate treatment of pain is associated
with postoperative complications and poor outcomes. Paracetamol,
nonsteroidal anti-inﬂammatory drugs (NSAIDs) like celecoxib and, if
necessary, opioids are the most commonly used drugs for periopera-
tive analgesia. Opioid use is avoided mainly because of the fear of side
effects such as respiratory depression, nausea, vomiting, urinary re-
tention, and pruritis (Scott and Perry, 2000). It was observed that an-
algesia induced by celecoxib in a model of inﬂammatory pain was, in
contrast with that induced by paracetamol could be reversed by opi-
oid receptor antagonist naloxone (França et al., 2006; Pickering et al.,
2011), suggesting that its antinociceptive effect is mediated by en-
dogenous opioids, presumably indirectly, involving release from
opioidergic nerves. Based on the present ﬁndings, mangiferin de-
serves a role in the management of post-operative pain.
Motor deﬁcits may create confounds in studies in which
antinociception is measured. To clarify if the analgesic effect is not a
result of motor deﬁcits, we assessed the effects of mangiferin on
open-ﬁeld and rota-rod tests that are classical models for screening
central nervous system actions providing information on motor coor-
dination and myorelaxant activity. Mangiferin (10–100 mg/kg, p.o.),
neither impaired locomotor activity in open-ﬁeld test nor presented
myorelaxant activity as demonstrated in the rota-rod test that mea-
sures grip strength, suggesting that the mangiferin antinociception
observed in this investigation is not exerted through peripheral neu-
romuscular blockade or induction of sedation.
Studies also have shown that mangiferin is free from cytotoxic
or genotoxic effects (Rodeiro et al., 2012). Acute toxicity in mice
showed that mangiferin was safe at an oral dose up to 25 g/kg (Niu
et al., 2012). These ﬁndings demonstrate that mangiferin has the
antinociceptive potential to be developed as a therapeutic agent.
Based on our results obtained in capsaicin model of nociception, it
was suggested that mangiferin's antinociception possibly involves
the participation of endogenous opioids, KATP-channels, and adeno-
sine receptors. Nevertheless, studies are warranted, using nociceptive
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antinociceptive mechanism and exploit the antinociceptive property
of this compound for clinical situations.5. Conclusions
This study demonstrated the antinociceptive activity of a
glucosylxanthone, mangiferin in experimental models of visceral pain
induced by intraperitoneal acetic acid, and in the inﬂammatory and
neurogenic pain evoked by subplantar formalin or intraplantar capsai-
cin inmice. In tests of thermal pain (hot-plate and tail-ﬂick),mangiferin
failed to manifest signiﬁcant antinociception, indicating that its action
is only peripheral and not central. The results also indicated that
mangiferin's antinociception possibly involves the participation of
endogenous opioids, KATP-channels, and adenosine receptors.Acknowledgments
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